123 related articles for article (PubMed ID: 21892040)
1. Preliminary study on the evaluation of olfactory neuroblastoma using PET/CT.
Wu HB; Wang QS; Zhong JM; Zhou WL; Li HS; Qiao-yu W
Clin Nucl Med; 2011 Oct; 36(10):894-8. PubMed ID: 21892040
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up using 18F-FDG PET/CT for postoperative olfactory neuroblastoma.
Fujioka T; Toriihara A; Kubota K; Machida Y; Nakamura S; Kishimoto S; Ohashi I; Shibuya H
Nucl Med Commun; 2014 Aug; 35(8):857-63. PubMed ID: 24751700
[TBL] [Abstract][Full Text] [Related]
3. The added value of 18F-FDG PET/CT for evaluation of patients with esthesioneuroblastoma.
Broski SM; Hunt CH; Johnson GB; Subramaniam RM; Peller PJ
J Nucl Med; 2012 Aug; 53(8):1200-6. PubMed ID: 22728262
[TBL] [Abstract][Full Text] [Related]
4. A case of olfactory neuroblastoma detected by (18)F-FDG PET/CT.
Tanaka K; Yamamoto Y; Hoshikawa H; Nishiyama Y
Clin Nucl Med; 2014 Jul; 39(7):635-6. PubMed ID: 24662664
[TBL] [Abstract][Full Text] [Related]
5. Utility of 18F-FDG PET/CT in the diagnosis and staging of extramammary Paget's disease.
Tian Y; Wu HB; Li DL; Li HS; Zhou WL; Wang QS
Nucl Med Commun; 2015 Sep; 36(9):892-7. PubMed ID: 25932540
[TBL] [Abstract][Full Text] [Related]
6. Role of
Elkhatib AH; Soldatova L; Carrau RL; Hachem RA; Ditzel L; Campbell R; Prevedello DM; Prevedello L; Filho LF; Campbell RG
Laryngoscope; 2017 Feb; 127(2):321-324. PubMed ID: 27481043
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-DOTATATE and 18F-FDG PET/CT for the Management of Esthesioneuroblastoma of the Sphenoclival Region.
Dadgar H; Norouzbeigi N; Ahmadzadehfar H; Assadi M
Clin Nucl Med; 2020 Aug; 45(8):e363-e364. PubMed ID: 32558717
[TBL] [Abstract][Full Text] [Related]
8. Utility of ¹¹C-choline imaging as a supplement to F-18 FDG PET imaging for detection of thyroid carcinoma.
Wu HB; Wang QS; Wang MF; Li HS
Clin Nucl Med; 2011 Feb; 36(2):91-5. PubMed ID: 21220968
[TBL] [Abstract][Full Text] [Related]
9. Bilateral Adrenal Hyperplasia Due to Adrenocorticotropic Hormone-Secreting Esthesioneuroblastoma on FDG PET and 111In-Pentetreotide Scintigraphy.
Matsusaka Y; Nakahara T; Kurihara I; Iwabuchi Y; Jinzaki M
Clin Nucl Med; 2018 Jun; 43(6):452-453. PubMed ID: 29659387
[TBL] [Abstract][Full Text] [Related]
10. Low positive yield from routine inclusion of the brain in whole-body 18F-FDG PET/CT imaging for noncerebral malignancies: results from a large population study.
Manohar K; Bhattacharya A; Mittal BR
Nucl Med Commun; 2013 Jun; 34(6):540-3. PubMed ID: 23503001
[TBL] [Abstract][Full Text] [Related]
11. High 18F-FDG Avidity of Low-Grade Esthesioneuroblastoma.
Jannin A; Turpin A; Baillet C; Aubert S; Do Cao C
Clin Nucl Med; 2018 Mar; 43(3):e101-e102. PubMed ID: 29293141
[TBL] [Abstract][Full Text] [Related]
12. F-18 FDG PET/CT staging and posttherapeutic assessment of esthesioneuroblastoma.
Nguyen BD; Roarke MC; Nelson KD; Chong BW
Clin Nucl Med; 2006 Mar; 31(3):172-4. PubMed ID: 16495744
[No Abstract] [Full Text] [Related]
13. [Evaluation of CT in the diagnosis of esthesioneuroblastoma].
Yuan Y; Peng S; Xie Z
Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):134-5. PubMed ID: 11776856
[TBL] [Abstract][Full Text] [Related]
14. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
15. Diagnosis of metastases from postoperative differentiated thyroid cancer: comparison between FDG and FLT PET/CT studies.
Nakajo M; Nakajo M; Jinguji M; Tani A; Kajiya Y; Tanabe H; Fukukura Y; Nakabeppu Y; Koriyama C
Radiology; 2013 Jun; 267(3):891-901. PubMed ID: 23468571
[TBL] [Abstract][Full Text] [Related]
16. ¹¹C-methionine and ¹⁸F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of patients with suspected primary and residual/recurrent gliomas.
Li DL; Xu YK; Wang QS; Wu HB; Li HS
Chin Med J (Engl); 2012 Jan; 125(1):91-6. PubMed ID: 22340472
[TBL] [Abstract][Full Text] [Related]
17. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic accuracy of lymph node metastasis depends on metabolic activity of the primary lesion in thoracic squamous esophageal cancer.
Manabe O; Hattori N; Hirata K; Itoh K; Hosokawa M; Takahashi H; Oyama-Manabe N; Tamaki N
J Nucl Med; 2013 May; 54(5):670-6. PubMed ID: 23516310
[TBL] [Abstract][Full Text] [Related]
19. [Diagnostic value of (18)F-FDG PET/CT imaging plus serum tumor marker assays for pulmonary lesions and clinical significance of SUVmax].
Zhang TM; Zhang LM; Liu Y; Zhang ZF; Wang CL
Zhonghua Yi Xue Za Zhi; 2012 Nov; 92(41):2901-4. PubMed ID: 23328236
[TBL] [Abstract][Full Text] [Related]
20. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy.
Berthet L; Cochet A; Kanoun S; Berriolo-Riedinger A; Humbert O; Toubeau M; Dygai-Cochet I; Legouge C; Casasnovas O; Brunotte F
J Nucl Med; 2013 Aug; 54(8):1244-50. PubMed ID: 23674577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
